2022
Multiscale PHATE identifies multimodal signatures of COVID-19
Kuchroo M, Huang J, Wong P, Grenier JC, Shung D, Tong A, Lucas C, Klein J, Burkhardt DB, Gigante S, Godavarthi A, Rieck B, Israelow B, Simonov M, Mao T, Oh JE, Silva J, Takahashi T, Odio CD, Casanovas-Massana A, Fournier J, Farhadian S, Dela Cruz C, Ko A, Hirn M, Wilson F, Hussin J, Wolf G, Iwasaki A, Krishnaswamy S. Multiscale PHATE identifies multimodal signatures of COVID-19. Nature Biotechnology 2022, 40: 681-691. PMID: 35228707, PMCID: PMC10015653, DOI: 10.1038/s41587-021-01186-x.Peer-Reviewed Original ResearchConceptsSingle-cell RNA sequencingTransposase-accessible chromatinSingle-cell sequencingRNA sequencingBiological insightsPopulation groupingsSophisticated computational toolsBiological featuresSequencingFlow cytometryComputational toolsChromatinBiomedical communityDifferent data typesCell responsesCellsPhate
2012
Onco-Nephrology: Tumor Lysis Syndrome
Wilson FP, Berns JS. Onco-Nephrology: Tumor Lysis Syndrome. Clinical Journal Of The American Society Of Nephrology 2012, 7: 1730-1739. PMID: 22879434, DOI: 10.2215/cjn.03150312.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTumor lysis syndromeLysis syndromeCancer cellsAcute myeloid leukemiaCytotoxic chemotherapyPrompt recognitionLymphoblastic leukemiaVolume repletionHematologic malignanciesMyeloid leukemiaBurkitt's lymphomaSecondary hypocalcemiaBlood streamHomeostatic mechanismsPatientsSyndromeLeukemiaTreatmentIntracellular contentHypocalcemiaCellsHyperkalemiaHyperphosphatemiaRasburicaseChemotherapy